Barclays raised the firm’s price target on NiSource (NI) to $44 from $42 and keeps an Overweight rating on the shares as part of a Q2 preview. The firm believes the company has made positive steps in the GenCo regulatory process. NiSource is well positioned for contracting upside in Q3, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NI: